



CCR Clinical Trials at NIH Committed to Cancer Research

Search
GO



You are here: [Clinical Trials at NIH](#) > [Health Care Professionals](#) > [Investigator Profiles](#) > Steven A. Rosenberg, M.D., Ph.D.

Clinical Research

[Search for Clinical Trials at NIH](#)

[Clinical Trials by Cancer Site](#)

[Clinical Trial Spotlight](#)

General Public

[Overview of Clinical Trials](#)

[How to Enroll in a Clinical Trial](#)

[Trial Participation Costs](#)

[General FAQs](#)

Health Care Professionals

[Refer a Patient](#)

[FAQs](#)

[Clinical Programs](#)

[Investigator Profiles](#)

[CCR Grand Rounds Lecture Series](#)

[Conferences & Events](#)

[In the News](#)

[Join Our Mailing List](#)

About

[Directions](#)

[Contact Us](#)

Additional Resources

[Printable Materials](#)

[Cancer Resources](#)

[Educational Materials](#)

[Clinical Trials at NIH Home](#)



Investigator Profiles

Steven A. Rosenberg, M.D., Ph.D.



Surgery Branch
Head, Tumor Immunology
Section
Branch Chief

National Cancer Institute
9000 Rockville Pike
Building 10, Room 3-3940
Bethesda, MD 20892

Phone:

301-496-4164

Fax: 301-402-1738

SAR@nih.gov

[Dr. Rosenberg](#) is Chief of Surgery at the National Cancer Institute (NCI) in Bethesda, Md., and a Professor of Surgery at the Uniformed Services University of the Health Sciences and at the George Washington University School of Medicine and Health Sciences in Washington, D.C. Dr. Rosenberg received his B.A. and M.D. degrees from The Johns Hopkins University in Baltimore, Md., and his Ph.D. in biophysics from Harvard University. After completing his residency training in surgery in 1974 at the Peter Bent Brigham Hospital in Boston, Mass., Dr. Rosenberg became Chief of Surgery at NCI, a position he has held to the present time.

Dr. Rosenberg's Clinical Trial(s):

NCI's Center for Cancer Research (CCR) is currently conducting the following trial(s) for patients with melanoma, kidney cancer, or solid tumors. Click on the trial(s) below for additional details, including a summary of key eligibility criteria, study outline, and information on how to contact the study team directly.

Clinical Trials

- [View](#) Dr. Rosenberg's Trial(s)
- See additional trials listed on [PDQ](#)
- Learn how to [Refer a Patient](#)

Clinical Trials Research

Dr. Rosenberg has pioneered the development of immunotherapy that has resulted in the first effective immunotherapies for selected patients with advanced cancer. He has also pioneered the development of gene therapy and was the first to successfully insert foreign genes into humans and to conduct clinical studies of the gene therapy of cancer.

[Read more](#)

- [View](#) Dr. Rosenberg's publications

Please contact my Team Coordinator(s) to make a referral:

June A. Kryk, R.N.
1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov

Linda Williams, R.N.
1-866-820-4505

(Toll Free)
ncisbirc@mail.nih.gov

- [Phase I/II Study of Metastatic Cancer that Expresses MAGE-A3/12 Using Lymphodepleting Conditioning Followed by Infusion of Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes](#)
[NCI-11-C-0062](#)
- [Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes](#)
[NCI-11-C-0013](#)
- [Phase I/II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of CD8 Enriched Tumor Infiltrating Lymphocytes Genetically Engineered to Express IL-12](#)
[NCI-11-C-0011](#)
- [A Phase II Study Using Short-Term Cultured, CD8+-enriched Autologous Tumor-Infiltrating Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Digestive Tract Cancers](#)
[NCI-10-C-0166](#)
- [Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-dose Aldesleukin in Metastatic Melanoma](#)
[NCI-10-C-0117](#)
- [Assessment of the Safety and Feasibility of Administering T cells Expressing an anti-CD19 Chimeric Antigen Receptor to Patients With B-cell Lymphoma or Leukemia](#)
[NCI-09-C-0082](#)
- [Phase II Study of Metastatic Melanoma Using a Chemoradiation Lymphodepleting Conditioning Regimen Followed by Infusion of Anti-Mart-1 and Anti-gp100 TCR-Gene Engineered Lymphocytes and Peptide Vaccines](#)
[NCI-09-C-0051](#)
- [Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes](#)
[NCI-08-C-0121](#)
- [Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 F5](#)

[TCR-Gene Engineered Lymphocytes and
ALVAC Virus Immunization](#)
[NCI-08-C-0056](#)

- [Phase II Study of Metastatic Melanoma
Using Lymphodepleting Conditioning
Followed by Infusion of Anti-gp100:154-162
TCR-Gene Engineered Lymphocytes and
ALVAC Virus Immunization](#)
[NCI-08-C-0055](#)
- [A Phase II Study Using Short-Term Cultured
Anti-Tumor Autologous Lymphocytes
Following a Lymphocyte Depleting Regimen
in Metastatic Melanoma](#)
[NCI-07-C-0176](#)

[^ Back to Top](#)

[Cancer.gov](#) | [Accessibility](#) | [Privacy](#) | [Directions](#) | [Contact Us](#)

